8.985  2.215 (32.72%)		05-14 11:49
Open: 6.57 High: 9.62 Volume: 121,566		Pre. Close: 6.77 Low: 6.57 Market Cap: 38(M)

Short term
Mid term
Targets	6-month :	11.23	1-year :	13.12
Resists	First :	9.61	Second :	11.23
Pivot price	7.13
Supports	First :	6.97	Second :	5.33
MAs	MA(5) :	7.39	MA(20) :	7.32
	MA(100) :	11.01	MA(250) :	30.53
MACD	MACD :	0.1	Signal :	0
%K %D	K(14,3) :	37.7	D(3) :	28.5
RSI	RSI(14): 63.6
52-week	High :	75.5	Low :	4.13

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ TVGN ] has closed above the upper band by 21.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 54% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	7.39 - 7.44	7.44 - 7.48
Low:	6.39 - 6.45	6.45 - 6.5
Close:	6.68 - 6.77	6.77 - 6.84

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Wed, 13 May 2026
Number of shareholders of Tevogen Bio Holdings Inc. – NASDAQ:TVGN - TradingView

Tue, 12 May 2026
Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP - Quiver Quantitative

Tue, 12 May 2026
Existing backer pays 14% premium in Tevogen’s new $3M cash raise - Stock Titan

Mon, 11 May 2026
TVGN Stock Price, Quote & Chart | TEVOGEN BIO HOLDINGS INC (NASDAQ:TVGN) - ChartMill

Mon, 11 May 2026
TVGN Technical Analysis | Trend, Signals & Chart Patterns | TEVOGEN BIO HOLDINGS INC (NASDAQ:TVGN) - ChartMill

Mon, 27 Apr 2026
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal - Sahm

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	4 (M)
Shares Float	1 (M)
Held by Insiders	74.3 (%)
Held by Institutions	2.7 (%)
Shares Short	91 (K)
Shares Short P.Month	86 (K)

EPS	-8.08
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-4.24
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-416.6 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-6.24
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-1.09
PEG Ratio	0
Price to Book value	-2.07
Price to Sales	0
Price to Cash Flow	-2.96

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.